NeuroSense Therapeutics Stock (NASDAQ:NRSN)
Previous Close
$0.98
52W Range
$0.51 - $1.50
50D Avg
$1.05
200D Avg
$1.06
Market Cap
$23.27M
Avg Vol (3M)
$140.53K
Beta
1.34
Div Yield
-
NRSN Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.